Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Replimune Group, Inc. - Common Stock
(NQ:
REPL
)
11.20
+5.79 (+107.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Replimune Group, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Top movers in Friday's session
↗
July 31, 2026
Via
Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
↗
July 31, 2026
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding...
Via
Benzinga
Top stock movements in today's session.
↗
July 31, 2026
Via
Chartmill
Gapping stocks in Friday's session
↗
July 31, 2026
Via
Chartmill
Friday's pre-market session: top gainers and losers
↗
July 31, 2026
Via
Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
July 31, 2026
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of...
Via
Benzinga
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
July 30, 2026
Advisory Committee voted 10 to 3 that the efficacy results from the IGNYTE study are evaluable and clinically meaningful
From
Replimune, Inc.
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm
July 30, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
July 29, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
Replimune Group Inc. (REPL) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
July 29, 2026
From
Law Offices of Howard G. Smith
Via
Business Wire
Securities Fraud Investigation Into Replimune Group Inc. (REPL) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
July 28, 2026
From
The Law Offices of Frank R. Cruz
Via
Business Wire
These stocks are moving in today's session
↗
July 28, 2026
Via
Chartmill
Top stock movements in today's session.
↗
July 28, 2026
Via
Chartmill
Which stocks are gapping on Tuesday?
↗
July 28, 2026
Via
Chartmill
Which stocks are moving before the opening bell on Tuesday?
↗
July 28, 2026
Via
Chartmill
Thursday's after hours session: top gainers and losers
↗
July 16, 2026
Via
Chartmill
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
June 29, 2026
From
Replimune, Inc.
Via
GlobeNewswire
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
June 26, 2026
FDA decision expected by August 2, 2026
From
Replimune, Inc.
Via
GlobeNewswire
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
↗
June 19, 2026
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s....
Via
InvestorPlace
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 31, 2026
From
Replimune, Inc.
Via
GlobeNewswire
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 30, 2026
From
Replimune, Inc.
Via
GlobeNewswire
Top stock movements in today's session.
↗
May 29, 2026
Via
Chartmill
Keep an eye on the top gainers and losers in Friday's session.
↗
May 29, 2026
Via
Chartmill
Friday's session: gap up and gap down stocks
↗
May 29, 2026
Via
Chartmill
Top movers in Friday's pre-market session
↗
May 29, 2026
Via
Chartmill
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
May 29, 2026
From
Replimune, Inc.
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
May 19, 2026
From
Pomerantz LLP
Via
GlobeNewswire
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
May 17, 2026
From
Schall Law
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL
May 12, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
April 28, 2026
From
Pomerantz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.